Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 5/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.66 |
| ▸ | KDR | P35968 | 4/20 | 0.61 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14967568 | 0.93 | PDGFRA (0.70) | PDGFRAPDGFRBKDRFGFR2EGFR | |
| SCHEMBL5054159 | 0.90 | PDGFRA (0.62) | PDGFRAPDGFRBKDRFGFR2 | |
| SCHEMBL25307750 | 0.90 | PDGFRA (0.62) | PDGFRAPDGFRBKDRFGFR2EGFR | |
| SCHEMBL31616944 | 0.90 | PDGFRA (0.62) | PDGFRAPDGFRBKDRFGFR2EGFR | |
| SCHEMBL5205515 | 0.90 | PDGFRA (0.62) | PDGFRAPDGFRBKDRFGFR2EGFR | |
| SCHEMBL3894407 | 0.88 | PDGFRA (0.59) | PDGFRAPDGFRBKDRFGFR2EGFR | |
| SCHEMBL558651 | 0.85 | PDGFRA (0.80) | PDGFRAPDGFRBKDRFGFR2 | |
| SCHEMBL19957221 | 0.82 | PDGFRA (0.55) | PDGFRAPDGFRBKDRFGFR2EGFR | |
| SCHEMBL166507 | 0.82 | PDGFRA (0.61) | PDGFRAPDGFRBKDRFGFR2EGFR | |
| SCHEMBL30106547 | 0.82 | PDGFRA (0.61) | PDGFRAPDGFRBKDRFGFR2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | PDGFRA 780/4885PDGFRB 641/4885KDR 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.